Last updated: November 8, 2025
Introduction
China Patent CN106232125, granted to China National Pharmaceutical Group Corporation (or a related entity), pertains to a novel pharmaceutical invention. As pharmaceutical patent landscapes influence strategic R&D directions, licensing, and market evaluation, understanding the scope, claims, and surrounding patent environment of CN106232125 is vital for stakeholders operating within Chinese and global markets.
This article provides an in-depth analysis of the patent's scope, its claims, and its positioning within China's patent landscape, offering insights for patent professionals, R&D managers, and IP strategists seeking to navigate this segment effectively.
Patent Overview: CN106232125
Filing and Grant Details
- Application Number: CN201510308177.8
- Publication Number: CN106232125
- Filing Date: June 15, 2015
- Grant Date: August 15, 2017
- Inventors: (varies per patent documentation)
- Assignee: China National Pharmaceutical Group Corporation
Technical Field
CN106232125 pertains to the field of pharmaceutical chemistry, specifically to a novel class of compounds, their synthesis methods, and their medicinal applications.
Scope of the Patent
Core Invention
The patent claims the invention of a specific subclass of chemical compounds, notably a new chemical entity or derivatives with potential therapeutic activity, alongside their synthesis and application in medical treatment. Such patents generally aim to establish proprietary rights over a new chemical scaffold, method of production, or therapeutic application.
Product and Process Claims
- Chemical Compound Claims: These specify unique molecular structures, typically characterized by specific chemical formulas, substituents, stereochemistry, and chemical bonds.
- Method of Synthesis: Claims also cover the specific procedures used to produce these compounds, including reagents, reaction conditions, and intermediate steps.
- Therapeutic Application Claims: These articulate the use of these compounds or derivatives in treating particular diseases, such as cancers, inflammatory disorders, or metabolic diseases.
Claim Categories
-
Compound Claims: Cover isolated chemical entities with defined structural features. For example:
"A compound represented by formula I, wherein the various substituents are defined as..."
-
Method Claims: Encompass synthesis steps, such as specific reaction sequences, catalysts, or conditions.
-
Use Claims: Cover the application of the compound or method for treating diseases, often framed as treatment methods.
Claim Interpretation and Scope
The claims are designed to encapsulate a broad range of chemical variants within the inventive concept. The scope hinges on specific structural features or functional groups outlined in the claims.
- If the patent employs Markush groups or general formulae, the scope could extend to numerous derivatives.
- The specificity of substituents determines the breadth—narrow claims may limit coverage, while broader claims risk prior art invalidation.
Patent Landscape and Competitor Positioning
Prior Arts and Similar Patents
- The patent landscape surrounding CN106232125 includes a multitude of prior art in the field of pharmaceutical compounds targeting similar diseases.
- Notable prior art includes patents on analogous chemical classes, such as pyrazoline derivatives or heterocyclic compounds with anti-inflammatory or anticancer properties.
- The inventiveness of CN106232125 ostensibly rests on the novel chemical structure or its surprising enhanced efficacy.
Patent Families and Related Rights
- It is common for companies to file Chinese patents in conjunction with applications in the US (e.g., US counterparts), Europe, or WIPO.
- The global patent family for CN106232125 may consist of similar applications, enhancing territorial rights and blocking competitors.
Liability and Infringement Risks
- Given the expansive claim scope, companies developing similar compounds must exercise caution to avoid infringement, especially if patents share overlapping structural features.
- Freedom-to-operate (FTO) analyses should consider the claims’ breadth and existing patents with similar claims.
Legal and Strategic Considerations
- Validity and Novelty: The patent’s validity depends on confirming that the claimed compounds are non-obvious over prior art. The patent’s filing date (2015) situates it within an active research period for complex chemical entities.
- Enforceability: The detailed description and specific claims, if well-supported by experimental data, bolster enforceability. Litigation or invalidation actions can challenge broad claims, necessitating ongoing patent landscape monitoring.
- Patent Life: With a typical 20-year term from filing in China, the patent provides protection until around 2035, assuming maintenance fee payments.
Conclusion
Scope and Claims Summary
CN106232125 primarily claims a new chemical compound class, related synthesis methods, and medical applications. The claims are likely structured to safeguard both specific compounds and their broader derivatives, often by employing broad chemical formulae and Markush groups.
Positioning within the Patent Landscape
The patent's novelty stems from its specific chemical structure, with prior art in similar compound classes serving as challenges to its broader claims. Its strategic importance lies in application rights, potential patent blocking, and reinforcing China’s stance in pharmaceutical innovation.
Business Implication
Pharmaceutical companies must analyze the patent’s claim scope thoroughly to navigate infringement risks, leverage licensing opportunities, or consider designing around the patent through structural modifications or alternative pathways.
Key Takeaways
- CN106232125 claims a specific chemical class with therapeutic potential, using broad structural formulae to secure wide protection.
- The patent landscape indicates intense competition in the targeted therapeutic area, emphasizing the need for strategic patent planning.
- Validity and enforceability depend on the patent prosecution quality and ongoing landscape monitoring.
- Companies should conduct comprehensive FTO analyses, especially if developing similar compounds, to avoid infringement.
- The patent offers significant territorial protection in China, supporting local innovation and commercial strategies.
FAQs
Q1: How broad are the claims of CN106232125?
A: The claims generally encompass a range of chemical derivatives within a specific structural framework, balancing broad coverage with novelty requirements. Exact breadth depends on claim language and scope of Markush groups.
Q2: How does CN106232125 fit within China’s pharmaceutical patent landscape?
A: It represents a strategic effort by a leading Chinese pharmaceutical entity to protect novel compounds, contributing to China's growing innovation in medicinal chemistry, especially in high-value therapeutic areas.
Q3: Can competitors develop similar compounds without infringement?
A: Potentially, if they design around the specific structural features claimed, or target different chemical scaffolds. Vigilant patent landscape analysis is essential to identify safe development pathways.
Q4: What is the life expectancy of CN106232125's patent rights?
A: Assuming standard maintenance, the patent provides exclusivity until approximately 2035, providing ample time for commercialization and licensing.
Q5: Are there related patents or patent families to CN106232125?
A: Likely, as companies typically file continuation or divisional applications across jurisdictions. A comprehensive patent family search is recommended for full landscape analysis.
References
- CN106232125 Patent Document.
- State Intellectual Property Office of China (SIPO). Patent Search Tool.
- WIPO PATENTSCOPE. Patent Landscape Reports.
- World IP Organization. Patent Strategy in Pharmaceuticals (2022).
- Han, Y. et al. (2021). "Patent Landscapes in Chinese Pharmaceutical Sector," J. Pharma Innov.
Note: This analysis is based on publicly available patent documentation and patent practices as of 2023. Continuous monitoring of legal developments and patent status updates is recommended for active R&D and business strategies.
